Related Experiment Videos
Improving Prospects for Targeting RAS
Harshabad Singh1, Dan L Longo1, Bruce A Chabner2
1Harshabad Singh and Bruce A. Chabner, Massachusetts General Hospital Cancer Center; Harshabad Singh, Dana-Farber Cancer Institute; and Dan L. Longo, Brigham and Women's Hospital, Boston, MA.
Abstract:
RAS mutations are among the most common oncogenic drivers in human cancers, affecting nearly a third of all solid tumors and around a fifth of common myeloid malignancies, but they have evaded therapeutic interventions, despite being the focus of intense research over the last three decades. Recent discoveries lend new understanding about the structure, function, and signaling of RAS and have opened new avenues for development of much needed new therapies. We discuss the various approaches under investigation to target mutant RAS proteins. The recent development of direct RAS inhibitors specific to KRAS G12C mutations represents a landmark discovery that promises to change the perception about RAS's druggability. Multiple clinical trials targeting synthetically lethal partners and/or downstream signaling partners of RAS are underway. Novel inhibitors targeting various arms of RAS processing and signaling have yielded encouraging results in the laboratory, but refinement of the drug-like properties of these molecules is required before they will be ready for the clinic.
Insights
Targeting RAS mutations in cancer, long a challenge, is now advancing with new direct inhibitors and synthetic lethality approaches. Research shows promise for novel therapies against these common cancer drivers.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- RAS mutations are prevalent oncogenic drivers in human cancers, present in approximately one-third of solid tumors and one-fifth of myeloid malignancies.
- Despite decades of research, targeting these RAS mutations therapeutically has remained a significant challenge.
- Recent breakthroughs in understanding RAS structure, function, and signaling have opened new therapeutic avenues.
Purpose of the Study:
- To review current and emerging therapeutic strategies targeting mutant RAS proteins.
- To highlight the significance of recent developments in direct RAS inhibition.
- To discuss the ongoing clinical trials and future directions for RAS-targeted therapies.
Main Methods:
- Review of recent scientific literature and clinical trial data.
- Analysis of novel inhibitor development for RAS processing and signaling pathways.
- Discussion of drug-like property refinement for clinical translation.
Main Results:
- The development of direct RAS inhibitors, particularly for KRAS G12C mutations, marks a significant advancement.
- Multiple clinical trials are actively investigating therapies targeting synthetic lethal partners or downstream effectors of RAS.
- Laboratory studies show encouraging results for novel inhibitors targeting various aspects of RAS processing and signaling.
Conclusions:
- Mutant RAS proteins are becoming increasingly druggable, shifting therapeutic paradigms.
- Further refinement of drug-like properties is necessary for the clinical readiness of novel RAS-targeting agents.
- Targeting RAS mutations holds significant promise for future cancer treatment strategies.